皮皮学,免费搜题
登录
logo - 刷刷题
搜题
【单选题】
Small, pink and very ugly. Hardly the qualities of a star, but they describe the deformed mouse that was the media darling at a recent science exhibition in Beijing. With a complex tissue structure in the shape of a human ear grafted on to its back, the rosy rodent was a stunning symbol of the serious strides China is making in the field of biotechnology. China is fast applying the latest life-science techniques learned from the West to aggressively pursue genome research. It's establishing its own centers of technical excellence to build a scientific base to compete directly with the United States and Europe. With a plentiful supply of smart young scientists at home and lots of interest abroad biotechnology is on the brink of a boom in China. And in the view of foreign scientists, Beijing is playing a clever hand, maximizing the opportunities open to them. For the moment, the cooperation exists mostly with Europe and the U.S. But Asia's other biotech leaders, Japan, Singapore and Korea, also are recognizing China's potential as an attractive low-cost base to conduct research. These partnerships——and China's advancement in the field of biotechnology——could help benefit the rest of Asia: China's rapid progress in improving crop yields will address food-security concerns in the region. In addition, China is more likely to focus on developing cheap technology that its predominantly poor population——and those of other Asian countries——can afford. There remain, however, serious barriers to the development of a strong biotech industry. Among them are a poor domestic legal framework, weak enforcement of intellectual-property rights and loose adherence to international standards. China is a signatory of the International Bio Safely Protocol, which should mean adherence to global standards governing the conduct of field trials. But some observers are skeptical. 'The regulations look good, but I haven't met one scientist who believes they are being fully adhered to,' says a European science analyst. If shortcuts are taken, then some of the recent scientific achievements trumpeted in the official press may never make it to market. But no matter how strict lab test are, other problems lie in wait. For example, there is a number of tasks it would take years to fulfill in the patents office, says one lawyer, leaving innovators with little protection if they take a product to market in China. The mouse on display is most significant in that ______.
A.
it has an ear in the shape of a human ear
B.
it is unusually small and ugly as a star
C.
it is the focus of the media at the exhibition
D.
it indicates China's progress in biotechnology
手机使用
分享
复制链接
新浪微博
分享QQ
微信扫一扫
微信内点击右上角“…”即可分享
反馈
参考答案:
举一反三
【单选题】关于嗜酸性粒细胞描述正确的是
A.
胞质的特殊颗粒含有组胺
B.
在发生急性细菌性炎症时显著增多
C.
来自多核巨细胞
D.
细胞核常分4~5叶
E.
嗜酸性颗粒电镜下为膜包颗粒,内含细颗粒状基质和长方形致密结晶体
【判断题】我们必须登陆秀米后,才能使用本地上传的图片素材库
A.
正确
B.
错误
【判断题】1940年,上海发行量最大的电影杂志《青青电影》举办“影迷心爱的影星”选举活动,陈云裳击败袁美云、陈燕燕、顾兰君等众女星,票数第一,当选“电影皇后”。( )
A.
正确
B.
错误
【单选题】关于超急性细菌性结膜炎的描述,何者不对
A.
起病急,病情进展快
B.
大量脓性分泌物
C.
主要致病菌是萘瑟淋球菌,萘瑟脑膜炎球菌
D.
一般无耳前淋巴结肿大
E.
眼睑高度红肿,结膜充血显著
【单选题】关于青霉素结合蛋白(PBPs)的描述丕正确的是
A.
某些细菌细胞膜具有PBPs
B.
当PBPs谱型发生改变则对β-内酰胺类抗生素产生抗药性
C.
当诱导产生新的PBPs时,则β-内酰胺类抗生素抗菌作用增强
D.
β-内酰胺抗生素与PBPs结合导致细菌变形死亡
E.
PBPs有多种类型
【单选题】下述关于抗眼部细菌感染药物的描述中,不正确的是
A.
对淋球菌性结膜炎可采用全身及眼局部抗菌药物治疗
B.
对于衣原体感染的治疗主要是抗菌药物治疗
C.
全身给予抗菌药物是眼科细菌感染疾病的首选方法
D.
细菌性眼内炎可采用玻璃体腔内注射方式给予抗菌药物
E.
左氧氟沙星可用于治疗眼部浅层感染
【多选题】关于青霉素结合蛋白(PBPs)的描述正确的是
A.
某些细菌细胞膜具有青霉素结合蛋白
B.
当PBPs谱型发生改变时对β-内酰胺类抗生素产生抗药性
C.
当诱导产生新的PBPs时,则β-内酰胺类抗生素抗菌作用增强
D.
β-内酰胺抗生素与PBPs结合导致细菌变形死亡
E.
PBPs有多种类型
【单选题】关于革兰阳性菌和阴性菌细胞壁结构的描述,正确的是
A.
革兰阴性菌肽聚糖含量丰富、壁厚、坚韧、有外膜
B.
革兰阴性菌肽聚糖含量少、壁薄,无外膜
C.
革兰阳性菌肽聚糖含量丰富、壁薄、无外膜
D.
革兰阳性菌肽聚糖含量少、壁厚、有外膜
E.
革兰阳性菌肽聚糖含量丰富、壁厚、无外膜
【判断题】1940 年 , 上海发行量最大的电影杂志《青青电影》举办“影迷心爱的影星”选举活动 , 陈云裳击败袁美云、陈燕燕、顾兰君等众女星 , 票数第一 , 当选“电影皇后”。()
A.
正确
B.
错误
【单选题】关于青霉素结合蛋白(PBPs)的描述不正确的是
A.
某些细菌细胞膜具有PBPs
B.
当PBPs谱型发生改变则对β-内酰胺类抗生素产生抗药性
C.
当诱导产生新的PBPs时,则β-内酰胺类抗生素抗菌作用增强
D.
β-内酰胺抗生素与PBPs结合导致细菌变形死亡
E.
PBPs有多种类型
相关题目:
参考解析:
知识点:
题目纠错 0
发布
创建自己的小题库 - 刷刷题